prt2527
·Code: PRT2527
prt2527: developed by 1 company · 1 clinical trial tracked.
prt2527 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect prt2527 to PRLD; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could prt2527 → PRLD affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Marginal Zone LymphomaT-cell Lymphoma
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Prelude Therapeutics Inc (PRLD) Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 |
Clinical Trials (1)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
Primary endpoint: Dose limiting toxicity (DLT) of PRT2527
Interventionalopen86 enrolledStarted 2023-09Completion 2026-0124 sites · Australia, Canada, France, Germany…Prelude Therapeutics
Frequently asked questions
Who is developing prt2527?
prt2527 is being developed by Prelude Therapeutics Inc.
How many clinical trials involve prt2527?
BioSniper tracks 1 clinical trial involving prt2527.